Calmodulin Regulates Fas-Mediated Apoptosis: A Target for Cancer Therapy
钙调蛋白调节 Fas 介导的细胞凋亡:癌症治疗的目标
基本信息
- 批准号:8195547
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-10-01 至 2013-09-30
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs DiseaseAnimal ModelApoptosisApoptoticBindingBiochemicalCASP8 geneCD95 AntigensCalciumCalmodulinCancer DiagnosticsCell DeathCellsCessation of lifeCharacteristicsChelating AgentsCholangiocarcinomaComplexCultured CellsDefectDevelopmentDiabetes MellitusDiagnosisDiagnostic testsDiseaseEarly DiagnosisEgtazic AcidExtrahepatic Bile DuctsFas Signaling PathwayGoalsHealthHepaticHepatobiliaryHumanIn VitroLeadMalignant NeoplasmsMediatingMediator of activation proteinMusNude MiceOperative Surgical ProceduresOsteoporosisPathogenesisPathway interactionsPatient CarePatientsPlayPopulationPrevention therapyProtein BindingProteinsProto-Oncogene Proteins c-aktReceptor SignalingRecruitment ActivityRegulationResistanceRoleSamplingSignal PathwaySignal TransductionTestingTherapeutic AgentsTimeTissue SampleTranslatingTumor Necrosis Factor Ligand Superfamily Member 6United StatesVeteransXenograft ModelXenograft procedureadvanced diseasebiliary tractcancer cellcancer therapychemotherapeutic agentcholangiocyteintrahepaticnovelnovel strategiesoverexpressionprotein complexreceptortherapeutic targettumortumorigenesis
项目摘要
6. Project Summary/Abstract. Cholangiocarcinoma is a highly malignant tumor that arises from
cholangiocytes of the intra- and extra-hepatic biliary system. Studies from our group and others have found
that modulating cell death/apoptosis pathways provide potential novel avenues for cholangiocarcinoma
therapy. Downregulating the death receptor (Fas) and upregulating Fas Ligand in cholangiocarcinoma cells
protect cells from apoptosis and enhance their tumorigenesis in mice. Further, several anti-apoptotic
mediators in the Fas signaling pathways, including protein kinase B/AKT and FLICE like Inhibitory Protein
(FLIP) are upregulated in cholangiocarcinoma cells, which render the cancer cells more resistant to apoptosis
and divert Fas-induced signaling to survival and proliferative pathways. With human cholangiocarcinoma
samples we demonstrated that the expression of Fas is associated with tumor differentiation. We have found
that antagonists of calmodulin (CaM) induce apoptosis of cholangiocarcinoma cells via a mechanism related to
the Fas-mediated apoptosis pathways and inhibit tumorigenesis in mice. Mechanistic studies further identified
Ca2+-dependent direct binding between CaM and Fas, which is regulated upon Fas-activation. In addition,
CaM is recruited into the Fas-activated death inducing signaling complex (DISC). A CaM antagonist and a
calcium chelator inhibit recruitment of CaM into the Fas-induced DISC and block the recruitment of FADD into
the DISC, suggesting that CaM/Fas binding contributes to Fas-activated DISC formation. Recently, we found
that CaM binds to FLIP, another DISC protein that is elevated in cholangiocarcinoma cells and activates
survival signals upon Fas activation. Therefore, we hypothesize that CaM is a critical regulator of the Fas-
death receptor signaling pathway and represents a potential therapeutic target for
cholangiocarcinoma. In this application, we will continue pursuing our long-term goal of understanding the
Fas death receptor signaling pathways in the pathogenesis of cholangiocarcinoma by focusing on determining
the role of CaM in regulating the Fas-activated DISC and the function of CaM/Fas and CaM/FLIP binding in
regulating proliferation and apoptosis of cholangiocarcinoma in culture and tumorigenesis in animal models.
The Specific Aims are: 1) characterize the function of CaM in regulating Fas signaling pathways in
cholangiocarcinoma cells; and 2) characterize the role of the CaM/Fas/FLIP interaction in regulating
cholangiocarcinoma tumorigenesis in mice. The present studies will define the fundamental mechanisms
by which CaM regulates signaling through the Fas pathway, thus facilitating further studies to translate these
findings into strategies and therapies for patient care. Considering that cancer is one of the important health
problems in the Veteran's population, our studies will lead to improvement of the health of veterans.
6. 项目总结/抽象。胆管癌是一种高度恶性肿瘤,起源于
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jay M. McDonald其他文献
Value-added laboratory medicine in an era of managed care.
管理式医疗时代的增值实验室医学。
- DOI:
- 发表时间:
1995 - 期刊:
- 影响因子:9.3
- 作者:
Jay M. McDonald;John A. Smith - 通讯作者:
John A. Smith
The effects of stasis with and without exercise on free calcium, various cations, and related parameters.
有或没有运动的停滞对游离钙、各种阳离子和相关参数的影响。
- DOI:
- 发表时间:
1980 - 期刊:
- 影响因子:0
- 作者:
B. Renoe;Jay M. McDonald;J. Ladenson - 通讯作者:
J. Ladenson
Regulation of Avian Osteoclastic H+-ATPase and Bone Resorption by Tamoxifen and Calmodulin Antagonists
他莫昔芬和钙调蛋白拮抗剂对禽破骨细胞 H-ATP 酶和骨吸收的调节
- DOI:
- 发表时间:
1996 - 期刊:
- 影响因子:4.8
- 作者:
John P. Williams;Harry C. Blair;M. McKenna;S. Jordan;Jay M. McDonald - 通讯作者:
Jay M. McDonald
A sensitive and precise isotopic assay of ATPase activity.
ATP 酶活性的灵敏且精确的同位素测定。
- DOI:
10.1016/0003-2697(78)90169-0 - 发表时间:
1978 - 期刊:
- 影响因子:2.9
- 作者:
Jonathan R. Seals;Jonathan R. Seals;Jay M. McDonald;Jay M. McDonald;David E. Bruns;David E. Bruns;Leonard Jarett;Leonard Jarett - 通讯作者:
Leonard Jarett
Direct effect of insulin on the labeling of isolated plasma membranes by [gamma32P] ATP.
胰岛素对 [gamma32P] ATP 标记分离质膜的直接影响。
- DOI:
10.1016/0006-291x(78)91372-4 - 发表时间:
1978 - 期刊:
- 影响因子:3.1
- 作者:
Jonathan R. Seals;Jonathan R. Seals;Jay M. McDonald;Jay M. McDonald;Leonard Jarett;Leonard Jarett - 通讯作者:
Leonard Jarett
Jay M. McDonald的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jay M. McDonald', 18)}}的其他基金
Calmodulin Regulates Fas-Mediated Apoptosis: A Target for Cancer Therapy
钙调蛋白调节 Fas 介导的细胞凋亡:癌症治疗的目标
- 批准号:
7911816 - 财政年份:2009
- 资助金额:
-- - 项目类别:
Calmodulin Regulates Fas-Mediated Apoptosis: A Target for Cancer Therapy
钙调蛋白调节 Fas 介导的细胞凋亡:癌症治疗的目标
- 批准号:
8391129 - 财政年份:2009
- 资助金额:
-- - 项目类别:
Calmodulin Regulates Fas-Mediated Apoptosis: A Target for Cancer Therapy
钙调蛋白调节 Fas 介导的细胞凋亡:癌症治疗的目标
- 批准号:
7798346 - 财政年份:2009
- 资助金额:
-- - 项目类别:
Notch Signaling and Prostate Cancer Bone Metastases
Notch信号传导和前列腺癌骨转移
- 批准号:
6814037 - 财政年份:2004
- 资助金额:
-- - 项目类别:
Notch Signaling and Prostate Cancer Bone Metastases
Notch信号传导和前列腺癌骨转移
- 批准号:
7234310 - 财政年份:2004
- 资助金额:
-- - 项目类别:
Notch Signaling and Prostate Cancer Bone Metastases
Notch信号传导和前列腺癌骨转移
- 批准号:
6944076 - 财政年份:2004
- 资助金额:
-- - 项目类别:
Notch Signaling and Prostate Cancer Bone Metastases
Notch信号传导和前列腺癌骨转移
- 批准号:
7105043 - 财政年份:2004
- 资助金额:
-- - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
-- - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
-- - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
-- - 项目类别: